Insulet Co. (NASDAQ:PODD) Stock Holdings Lifted by First Light Asset Management LLC

First Light Asset Management LLC raised its position in shares of Insulet Co. (NASDAQ:PODD) by 42.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 215,637 shares of the medical instruments supplier’s stock after purchasing an additional 64,373 shares during the period. Insulet accounts for about 3.8% of First Light Asset Management LLC’s investment portfolio, making the stock its 8th largest position. First Light Asset Management LLC owned approximately 0.31% of Insulet worth $43,516,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in shares of Insulet by 0.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 124,280 shares of the medical instruments supplier’s stock worth $26,968,000 after purchasing an additional 834 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Insulet by 15.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 7,487 shares of the medical instruments supplier’s stock worth $1,624,000 after purchasing an additional 982 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Insulet by 37.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,479 shares of the medical instruments supplier’s stock worth $2,274,000 after buying an additional 2,856 shares during the last quarter. UBS Group AG raised its holdings in Insulet by 0.9% during the fourth quarter. UBS Group AG now owns 61,404 shares of the medical instruments supplier’s stock valued at $13,323,000 after buying an additional 535 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of Insulet by 72.7% in the fourth quarter. Corient Private Wealth LLC now owns 8,053 shares of the medical instruments supplier’s stock worth $1,747,000 after buying an additional 3,389 shares during the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $234.00 price objective on shares of Insulet in a report on Tuesday, July 23rd. Barclays boosted their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. BTIG Research cut their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, UBS Group upped their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $229.21.

Insulet Trading Up 1.0 %

PODD stock opened at $238.97 on Tuesday. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $243.98. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The business’s 50 day moving average is $203.68 and its 200-day moving average is $188.92. The firm has a market cap of $16.75 billion, a P/E ratio of 72.42, a P/E/G ratio of 4.38 and a beta of 1.21.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. Equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.